Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paper

Jennifer Pinney; Candice Roufosse; Andreas Kousios; Aristeidis Chaidos; Julian D Gillmore; Francesco Rainone; Satarupa Choudhuri; Karthik Ramasamy; Sarah Blakey; John Ashcroft; Y L Tracey Chan; Paul Cockwell; Guy Pratt; BSH Committee

doi:10.1111/bjh.19956

Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paper

Br J Haematol. 2025 Jan 7. doi: 10.1111/bjh.19956. Online ahead of print.

Affiliations

¹ Department of Renal Medicine, University Hospital Birmingham NHS Trust, Birmingham, UK.
² Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
³ Department of Immunology and Inflammation, Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Imperial College London and Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
⁴ UK National Amyloidosis Centre, University College London, London, UK.
⁵ The Northern Care Alliance NHS Foundation Trust, Greater Manchester, UK.
⁶ Oxford University Hospital NHS Trust, and Oxford Translational Myeloma Centre, NDORMS, University of Oxford, Oxford, UK.
⁷ Department of Haematology, Mid Yorkshire Teaching Trust, Wakefield, UK.

PMID: 39777620
DOI: 10.1111/bjh.19956

Abstract

This guideline provides consensus opinion on the investigations required for people presenting with suspected monoclonal gammopathy of renal significance to both nephrology and haematology physicians. The guideline discusses the principles of treating a patient with MGRS and provides recommendations for both supportive management and haematological therapy. It details the recommended on-going monitoring required for both specialty areas.

Keywords: amyloidosis; cryobulinaemia; fibrillary glomerulonephritis; light chain deposition disease; monoclonal gammopathy of renal significance.